Supplementary Figure 1: Effects of the EP2/EP4 antagonists AH6809/GW627368X
on MEK and ERK activation in BxPC-3 cells. BxPC-3 cells were treated with 0.5 and 5
M AH6809/GW627368X for 3 h and the levels of phosphorylated MEK and ERK were determined by immunoblotting. 
Supplementary Materials and Methods

Effect of AH6809/GW627368X on the activation of MEK and ERK in BxPC-3 cells
BxPC-3 cells (3 × 10 5 cells/well) were plated onto six-well plates, preincubated overnight at 37°C, and then starved for 24 h in 1.5 mL of serum-free medium.
Subsequently, the cells were treated with AH6809 and GW627368X (0.5 and 5 M, respectively) for 3 h at 37°C. After treatment, the cells were subjected to immunoblotting for phospho-MEK, MEK, phospho-ERK, ERK, and actin.
EP4 knockdown studies
BxPC-3 cells (3 × 10 5 cells/well) were seeded onto six-well plates and preincubated overnight at 37°C. The following day, the cells were transfected with negative universal control siRNA and EP4 siRNA (ID SASI_Hs01_00105507; Sigma)
using Lipofectamine RNAiMAX, according to the manufacturer's protocol. After transfection, the cells (5 × 10 3 or 3 × 10 5 cells/well) were re-plated onto 96-well microplates or six-well plates. After preincubation overnight, the cells were starved for 24 h in serum-free medium and then stimulated with IGF-1 for 48 h or 20 min. Cell growth and the phosphorylation of MEK and ERK were determined by MTT assays and immunoblotting, respectively.
Effect of BX912 on the AH6809/GW627368X-mediated abrogation of
IGF-1-induced cellular growth and signaling
The effect of BX912 on cell viability was determined by MTT assays. BxPC-3 cells (5 × 10 3 cells/well) were plated onto 96-well microplates, preincubated overnight at 37°C, and then treated with 1, 10, or 100 nM BX912 (SYNkinase, San Diego, CA) for 48 h in serum-free medium at 37°C. After treatment, the viable cells were counted using the MTT method. The effect of BX912 on the AH6809/GW627368X-mediated abrogation of IGF-1-induced cellular growth and signaling was determined based on growth stimulation assays and immunoblotting. Briefly, BxPC-3 cells (5 × 10 3 or 3 × 10 5 cells/well) were plated onto 96-well microplates or six-well plates. After preincubation overnight, the cells were starved for 24 h in serum-free medium and then stimulated with IGF-1 for 48 h or 20 min in the absence or presence of AH6809/GW627368X and BX912 (100 nM) pretreatment for 3 h. Cell growth and the phosphorylation of PKC-, MEK, and ERK were then determined by MTT assays and immunoblotting, respectively.
Establishment of stable transfectants expressing hmIGF-1
Total RNA was isolated from human Ewing sarcoma SK-ES-1 cells and cDNA that contained the complete coding sequence of human mature IGF-1 (hmIGF-1) was synthesized and amplified by PCR, as previously described [47] . The PCR products were digested with EcoRI and BamHI, and then subcloned into pFUSE-hFc2 (IL2ss) vectors (Invivogen, San Diego, CA). Secondary PCR was then performed using this construct as a template. The PCR products were then digested with AgeI and NotI, and the products were subcloned into pIRESneo3 vectors (Clontech, Mountain View, CA).
The construct obtained was designated as pIRES-hmIGF1. Successful constructs were confirmed by direct sequencing with an ABI PRISM 3130xl Genetic Analyzer (Life Technologies). The primer sequences are listed in Supplementary Table 3 . BxPC-3 cells were transfected with pIRESneo3 or pIRES-hmIGF1 using Lipofectamine LTX (Life Technologies), according to the manufacturer's protocol. Transfected cells were treated with 1 mg/mL G418 sulfate (Promega, Madison, WI) every 3 days for 2 weeks. After selection, the stable transfectants were maintained in complete CM containing 0.1 mg/mL G418 sulfate and designated as BxPC-mock and BxPC-hmIGF1 cells, respectively. The BxPC-hmIGF1 cells were examined using hIGF-1 ELISA, cell proliferation assays, tests of proliferative reactions after treatment with AH6809/GW627368X, and in vivo growth assays in an orthotopic xenograft model.
These methods are described below.
In vitro characteristics of BxPC-hmIGF1
hIGF ELISA was performed in CM from BxPC-mock and BxPC-hmIGF1 cells (4 × 10 5 /2 mL/72 h in complete or serum-free CM), and the production of hIGF-1 was quantified using a Quantikine human IGF-1 ELISA kit (R&D Systems, Minneapolis, MN). Cell proliferation assays with BxPC-mock and BxPC-hmIGF1 cells (5 × 10 3 cells/well) were performed after seeding the cells onto 96-well microplates and preincubating overnight at 37°C. Subsequently, CM was replaced with 100 L fresh complete medium. After incubation for 24, 48, and 72 h, the viable cells were counted using the MTT method. Tests of the proliferative responses to treatments with AH6809/GW627368X were performed in BxPC-mock and BxPC-hmIGF1 cells (5 × 10 3 cells/well) after seeding onto 96-well microplates and preincubating overnight at 37°C. CM was then replaced with 100 L of serum-free medium and cells were further incubated overnight at 37°C. Finally, the AH6809/GW627368X and incubated for 48 h before counting the viable cells using the MTT method.
In vivo characteristics of BxPC-hmIGF-1
In vivo growth assays were performed in an orthotopic nude mouse xenograft model.
The mice were anesthetized with ketamine/xylazine and BxPC-mock or BxPC-hmIGF1 cells (1 × 10 6 cells/mouse) were injected intrapancreatically (n = 5 in the BxPC-mock group and n = 5 in the BxPC-hmIGF1 group). After 42 days of observation, the mice were euthanized and the tumor lesions were collected and weighed. The tumors were then fixed in 10% phosphate-buffered formaldehyde for the histological analyses.
Whole blood was also collected from all the mice and sera were obtained. hIGF ELISA was performed to assess the persistence of hmIGF-1 expression. Formaldehyde-fixed tissues were embedded in paraffin and sectioned at 4 m. All of the sections were subjected to H&E staining and immunohistochemical staining for IGF-1 and Ki-67.
Quantitative analyses were microscopically performed by counting the number of Ki-67-positive cells per field.
